These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21913899

  • 1. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.
    Dumas M, Nadal-Wollbold F, Gaussem P, Perez M, Mirault T, Létienne R, Bourbon T, Grelac F, Le Grand B, Bachelot-Loza C.
    Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
    Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, Yamanaka T, Seki J, Miyata S, Mutoh S.
    Eur J Pharmacol; 2003 Jul 25; 473(2-3):163-9. PubMed ID: 12892834
    [Abstract] [Full Text] [Related]

  • 3. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
    Wielders SJ, Bennaghmouch A, Reutelingsperger CP, Bevers EM, Lindhout T.
    J Thromb Haemost; 2007 Mar 25; 5(3):571-6. PubMed ID: 17166251
    [Abstract] [Full Text] [Related]

  • 4. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K, Ohnishi T, Miura N, Sameshima H, Koide T, Tanaka KA, Maruyama I.
    Thromb Res; 2014 Jan 25; 133(1):66-72. PubMed ID: 24268424
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Niitsu Y, Jakubowski JA, Sugidachi A, Asai F.
    Semin Thromb Hemost; 2005 Apr 25; 31(2):184-94. PubMed ID: 15852222
    [Abstract] [Full Text] [Related]

  • 6. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
    Nadal-Wollbold F, Bocquet A, Bourbon T, Létienne R, Le Grand B.
    Eur J Pharmacol; 2010 Oct 10; 644(1-3):188-94. PubMed ID: 20655904
    [Abstract] [Full Text] [Related]

  • 7. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.
    J Cardiovasc Pharmacol; 1997 Aug 10; 30(2):261-72. PubMed ID: 9269956
    [Abstract] [Full Text] [Related]

  • 8. Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat.
    Létienne R, Leparq-Panissié A, Calmettes Y, Nadal-Wollbold F, Perez M, Le Grand B.
    Biochem Pharmacol; 2010 Jun 01; 79(11):1616-21. PubMed ID: 20188709
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL, Arthur JF, Lee H, Nesbitt WS, Andrews RK, Gardiner EE, Hamilton JR.
    J Thromb Haemost; 2016 Aug 01; 14(8):1642-54. PubMed ID: 26878340
    [Abstract] [Full Text] [Related]

  • 10. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M, Matsuoka T, Kawata T, Kuramochi H, Kawaguchi S, Murakami K, Hiyoshi H, Suzuki S, Kawahara T, Kajiwara A, Hishinuma I.
    Eur J Pharmacol; 2011 Apr 25; 657(1-3):131-7. PubMed ID: 21300059
    [Abstract] [Full Text] [Related]

  • 11. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H.
    Br J Pharmacol; 2000 Apr 25; 129(7):1439-46. PubMed ID: 10742300
    [Abstract] [Full Text] [Related]

  • 12. Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.
    Van Doren L, Nguyen N, Garzia C, Fletcher EK, Stevenson R, Jaramillo D, Kuliopulos A, Covic L.
    Arterioscler Thromb Vasc Biol; 2021 Jan 25; 41(1):e33-e45. PubMed ID: 33267659
    [Abstract] [Full Text] [Related]

  • 13. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
    Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, Horn C, Michaux J, Marrot S, Letienne R, Pignier C, Bocquet A, Nadal-Wollbold F, Cussac D, de Vries L, Le Grand B.
    J Med Chem; 2009 Oct 08; 52(19):5826-36. PubMed ID: 19791800
    [Abstract] [Full Text] [Related]

  • 14. Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4-Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis.
    Li S, Wang W, Lin L, Yang L, Cai Y, Yang X, Zhang T, Xiao C, Yan H, Gao N, Zhao J.
    Arterioscler Thromb Vasc Biol; 2023 Feb 08; 43(2):253-266. PubMed ID: 36519467
    [Abstract] [Full Text] [Related]

  • 15. Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin.
    Hosokawa K, Ohnishi T, Kawakami A, Wakabayashi S, Koide T.
    J Thromb Haemost; 2005 Dec 08; 3(12):2703-11. PubMed ID: 16246253
    [Abstract] [Full Text] [Related]

  • 16. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN, Sauermelch CF, Rycyna R, Sarkar S, Feuerstein GZ, Nichols AJ, Ohlstein EH.
    Stroke; 1992 May 08; 23(5):703-11. PubMed ID: 1605806
    [Abstract] [Full Text] [Related]

  • 17. WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor.
    Cao C, Yang Q, Xia X, Chen Z, Liu P, Wu X, Hu H, Ding Z, Li X.
    Thromb Res; 2024 Jun 08; 238():41-51. PubMed ID: 38669962
    [Abstract] [Full Text] [Related]

  • 18. Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
    Ting HJ, Khasawneh FT.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):249-54. PubMed ID: 20858477
    [Abstract] [Full Text] [Related]

  • 19. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L.
    Thromb Haemost; 1994 Apr 15; 71(4):511-6. PubMed ID: 8052972
    [Abstract] [Full Text] [Related]

  • 20. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T, Hashizume H, Ogawa T, Okayama T, Nukui E, Oshima K, Morikawa T, Hagiwara M.
    Arzneimittelforschung; 1997 Jan 15; 47(1):13-8. PubMed ID: 9037437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.